JP Morgan Chase
MLYS icon

JP Morgan Chase’s Mineralys Therapeutics MLYS Stock Holding History

JP Morgan Chase’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Buy
51,922
+5,239
+11% +$154K ﹤0.01% 4471
2025
Q4 		$1.69M Sell
46,683
-136,997
-75% -$5.49M ﹤0.01% 4214
2025
Q3 		$6.97M Buy
183,680
+158,180
+620% +$3.42M ﹤0.01% 3065
2025
Q2 		$345K Buy
25,500
+4,946
+24% +$71.7K ﹤0.01% 4958
2025
Q1 		$326K Sell
20,554
-483,036
-96% -$5.56M ﹤0.01% 5025
2024
Q4 		$6.2M Buy
503,590
+482,174
+2,251% +$6.3M ﹤0.01% 3162
2024
Q3 		$259K Sell
21,416
-685
-3% -$8.29K ﹤0.01% 5289
2024
Q2 		$259K Buy
22,101
+3,363
+18% +$42.4K ﹤0.01% 5018
2024
Q1 		$242K Sell
18,738
-4,825
-20% -$59.6K ﹤0.01% 5248
2023
Q4 		$203K Buy
23,563
+14,479
+159% +$114K ﹤0.01% 5383
2023
Q3 		$86.4K Sell
9,084
-1,736
-16% -$22.6K ﹤0.01% 5576
2023
Q2 		$184K Buy
10,820
+1,551
+17% +$23.2K ﹤0.01% 5120
2023
Q1 		$145K Buy
+9,269
New +$156K ﹤0.01% 5255

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

JP Morgan Chase's MLYS Position: Q1 2026 in Review

JP Morgan Chase increased its Mineralys Therapeutics (MLYS) stake by 11% in Q1 2026, buying an estimated $154K and bringing the position to 51,922 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #4471.

JP Morgan Chase first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $6.97M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • JP Morgan Chase held 51,922 shares of Mineralys Therapeutics worth $1.22M as of Q1 2026.
  • JP Morgan Chase bought 5,239 Mineralys Therapeutics shares in Q1 2026, an estimated $154K.
  • Mineralys Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4471 holding.
  • JP Morgan Chase first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • JP Morgan Chase's Mineralys Therapeutics position peaked at $6.97M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.